Cartesian Therapeutics (RNAC) announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Cartesian Therapeutics develops mRNA cell therapies for autoimmune diseases, leveraging three modalities: mRNA CAR-T, mRNA MSC, and mRNA in situ. Lead asset Descartes-08 targets myasthenia gravis ...

Trial on track to commence in 1H25FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage ...

FREDERICK, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research note issued on Monday,Benzinga reports.

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases ...

Cartesian Therapeutics, Inc. (RNAC) stock price is 19.35 and Cartesian Therapeutics, Inc. (RNAC) 10-day simple moving average is 18.79. Cartesian Therapeutics, Inc. (RNAC) stock price is 19.35 and ...